GLP-1 Weight Loss: What Clinical Data Actually Shows

Last reviewed: June 1, 2026

Last updated: June 1, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

There is no single answer to how much weight you will lose on GLP-1 medications—clinical trials show weight loss ranging from 5% to 22% of body weight, depending on individual factors including starting weight, baseline metabolic health, medication adherence, lifestyle changes, and genetic variations in GLP-1 and related peptide pathways.

This variability matters because it shifts the conversation from 'which GLP-1 is strongest' to 'which factors predict my individual response.' Understanding your unique predispositions—genetic, metabolic, and behavioral—allows for more informed treatment decisions with your healthcare provider rather than relying on average outcomes.

What Clinical Trials Actually Show About GLP-1 Weight Loss

Landmark trials for semaglutide (SUSTAIN series) and tirzepatide (SURMOUNT series) demonstrated mean weight loss of 10-15% over 68 weeks, but this masks the reality: some participants lost as little as 5%, while others exceeded 20%. These averages reflect heterogeneous populations with different metabolic baselines, medication tolerances, and lifestyle engagement.

The STEP and SURMOUNT trials also revealed a dose-response relationship, meaning higher doses generally produced greater weight loss—but not uniformly across all participants. Importantly, weight loss often plateaus, and continued medication use typically maintains weight rather than producing indefinite loss.

Factors That Predict Your Individual Weight Loss Outcome

Your weight loss on GLP-1 therapy depends on multiple interconnected variables: baseline metabolic rate, insulin sensitivity, appetite regulation capacity, gastrointestinal tolerance (which affects adherence), dietary compliance, physical activity, sleep quality, stress levels, and genetic variation in appetite-suppression and energy-metabolism pathways. No single factor determines outcome; outcomes emerge from their combination.

Factor Category	Impact on Weight Loss
Baseline BMI and metabolic health	Higher baseline weight and better metabolic flexibility typically associate with greater percentage loss
Gastrointestinal tolerance	Nausea or constipation causing dose reduction or discontinuation directly limits weight loss potential
Dietary behavior change	GLP-1 suppresses appetite, but caloric intake still matters; participants with intentional diet changes lost more
Genetic variation in GLP1R, GIPR, MC4R	Predispositions in appetite-regulation genes may influence individual medication response and weight loss trajectory
Adherence duration	Weight loss accelerates during weeks 1-16, then slows; stopping medication typically results in weight regain
Exercise and activity level	Combined with GLP-1, structured physical activity enhances loss; sedentary baseline predicts smaller percentage loss

Why Genetic Testing Can Inform Your Realistic Expectations

Genetic variation in GLP-1 receptor (GLP1R), glucose-dependent insulinotropic polypeptide receptor (GIPR), and melanocortin-4 receptor (MC4R) genes influences how your body's appetite and energy systems respond to GLP-1 class medications. Specific variants in these pathways may help provide context for why some individuals experience rapid, sustained appetite suppression while others show more modest responses.

The Precision Peptide Genetic Test identifies your predispositions in these key peptide-pathway variants. This information should be interpreted with a qualified healthcare provider to support a more personalized conversation about realistic weight loss timelines, medication selection, and whether combination therapies (like dual-agonist compounds) might align better with your genetic profile.

Who Loses the Most Weight, and Safety Considerations for Realistic Planning

Clinical data suggests participants with higher baseline BMI (≥35), good gastrointestinal tolerance, excellent medication adherence, and intentional lifestyle changes (dietary calorie reduction, regular exercise) tend to achieve weight loss in the 15-22% range. Those with lower starting weight, early gastrointestinal side effects, or minimal lifestyle engagement typically see 5-10% loss. Neither outcome is a failure; both can meaningfully improve metabolic health.

Safety matters: GLP-1 medications are not appropriate for all patients (contraindicated in personal or family history of medullary thyroid cancer or MEN2 syndrome). Potential side effects including nausea, constipation, dehydration, and muscle loss can affect adherence and outcomes. A qualified provider should evaluate your eligibility, monitor your response, and adjust your treatment plan—including dose and medication type—based on your individual tolerance and progress.

How PlexusDx Supports a More Personalized Approach

PlexusDx recognizes that predicting your personal weight loss requires understanding both clinical averages and your individual genetic and biomarker context. Our approach integrates compounded GLP-1 medications (semaglutide and tirzepatide options) with genetic insights into peptide-pathway predispositions, allowing your provider to make more tailored recommendations rather than relying on trial-based population averages.

The Precision Peptide Genetic Test examines your variants in GLP1R, GIPR, FTO, and MC4R genes—all involved in appetite regulation and energy metabolism. These predispositions may help provide context for your expected medication response, but they do not predict your exact weight loss outcome. Genetics is one input; your lifestyle, adherence, and medical history matter equally. Your results should be interpreted with your healthcare provider as part of a comprehensive assessment.

Understanding your genetic predispositions in peptide pathways, combined with your medical history and lifestyle capacity, can support a more informed conversation with your provider about which medication (compounded semaglutide, tirzepatide, or a dual-compound option like GLP-Squared) and which dosing tier may align best with your goals and predicted response pattern.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Oral starts at $279/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.